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Dear Editor 21 
 22 
Circulating tumour cells (CTCs) have been hypothesised to be mediators of 23 
metastases [1] but, with numbers as low as one per 107 white cells [2], their utility as 24 
biomarkers has been limited by low rates of detection and isolation. CTCs have been 25 
identified in patients with metastatic neuroendocrine tumours (NETs) using the FDA-26 
cleared CellSearch (Janssen Diagnostics) technology, a semi-automated platform 27 
that uses immunomagnetic enrichment of CTCs based on expression of epithelial 28 
cell adhesion molecule (EpCAM) [3]. Using this platform, CTCs were found  in 36% 29 
of patients with pancreatic NETs and 53% of those with midgut NETs.  The presence 30 
of CTCs is associated with a worse overall survival, and early changes in CTC 31 
number following treatment in NET patients are also prognostic [4, 5].  CTCs may 32 
also be considered as ‘liquid biopsies’, offering the opportunity to interrogate the 33 
molecular characteristics of the tumour.  For such an approach to be broadly 34 
applicable, alternative technologies are required to increase number of CTCs 35 
isolated and the proportion of patients in which they can be detected.  36 
 37 
The CellCollector (GILUPI GmbH) is a novel medical device consisting of a 160mm 38 
sterile steel wire of which the terminal 20mm is coated with anti-EpCAM antibodies 39 
covalently coupled to a gold and hydrogel layer. The CellCollector is inserted into a 40 
peripheral vein enabling the circulating blood volume to be sampled. The wire is 41 
stained with fluorescently labelled antibodies and examined microscopically to 42 
identify CTCs. The clinical application of this device has been previously reported in 43 
patients with breast and lung cancer [6]  44 
  45 
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In this study we sought to compare the performance of the CellCollector and 46 
CellSearch in patients with metastatic NETs. Thirty-four patients provided written 47 
informed consent and were recruited into the study (Figure 1A). The protocol was 48 
approved by the central ethical review board (IRAS Project ID 105772). The 49 
CellCollector was inserted into the cubital vein via a 20G cannula and left in situ for 50 
30 minutes after which it was removed, washed in phosphate buffered saline (PBS) 51 
and fixed in acetone. The cells were permeabilized  (Triton X-100 in PBS, 0.1% 52 
concentration) at room temperature, washed in PBS and incubated with blocking 53 
buffer (bovine serum albumin (BSA)/PBS,3% concentration). Immunostaining was 54 
performed with a solution containing FITC conjugated antibodies against EpCAM 55 
[1:50; HEA125, Acris antibodies, Germany], cytokeratin 19 conjugated with Alexa488 56 
(1:50, A53-B/A2, Life technologies Corporation, US), pan-cytokeratin-Alexa488 57 
(1:50, C11,eBioscience, California) and cytokeratin 7-FITC (1:50, LP5K 58 
Milipore,MA). An Alexa-Fluor 647 conjugated anti-CD45 rabbit polyclonal antibody 59 
was added as negative marker to exclude white blood cells (1:25, MEM-28Exbio, 60 
Czech Republic). Finally, the wire was incubated in the nuclear stain, Hoesch 33342 61 
(Sigma), (concentration 1ug/ml). The wire was examined  in a bespoke holder 62 
allowing  inspection in four planes using an Axio Imager microscope with digital 63 
camera and AxioVision software.  64 
 65 
CTCs were defined according to the following criteria: 1. Intact cellular morphology , 66 
2. Cell diameter more than 4 µm, 3. Positive for cytokeratin and nuclear stain, but 67 
negative for CD45, 4. Nuclear stain distinct from the cytokeratin or EpCAM staining. 68 
Examples of positively identified CTCs are shown in Figure 1B. The number of CTCs 69 
was enumerated by two independent operators who were blind to the patient’s 70 
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clinical information. Where there was disagreement between the two operators, a 71 
third operator arbitrated. A 7.5 ml peripheral blood sample was collected 72 
concurrently into a CellSave tube and analysed within 72 hours by CellSearch as 73 
previously described [3].  74 
 75 
The interobserver variation for CellSearch has been previously reported [7], and here 76 
we demonstrated good correlation between observers enumerating CTCs using the 77 
CellCollector achieving Spearman’s correlation of 0.92 (95% CI 0.85, 0.96) (p < 78 
0.0001) (Figure 1C). The median number of CTCs enumerated with CellCollector 79 
was 6 (range 2-49), compared to a median of 0 (range 0-57) with CellSearch 80 
(P<0.0001[Mann Whitney U test]). In 33/34 patients, there was ≥1 CTC found 81 
compared to only 16/34 patients with CellSearch. (Table 1). Therefore, CTCs were 82 
detected in  greater numbers and a greater proportion of patients with the 83 
CellCollector (Figure 1D). The CellCollector identified CTCs in all midgut NETs, and 84 
12/13 PNETS.  85 
 86 
We  explored the prognostic relevance of CTC count according to CellCollector. With 87 
a median follow-up period of 13 months, overall survival data was insufficiently 88 
mature so we examined progression free survival (PFS) as a surrogate.  Overall, 14 89 
patients had progression by RECIST criteria and applying a cut-off of 7 CTCs, there 90 
was a significant difference in PFS (Cox Hazard Ratio 3.4, P<0.05). Using the same 91 
threshold in the Kaplan Meier survival analyses (Figure 1E), median PFS was 11  92 
months  for patients with ≥7CTCs but not reached for those with <7 (Log Rank 93 
P<0.05).  94 
 95 
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Here, we have demonstrated for the first time, that the CellCollector is able to detect 96 
CTCs in in more NET patients and in greater numbers than CellSearch. However, 97 
the CellSearch has been extensively validated and remains a robust method for 98 
prognostication whilst the CellCollector offers the potential to make molecular 99 
analysis of CTCs more widely applicable. Indeed, a recent study in lung cancer 100 
demonstrated both KRAS and EGFR mutations known to be present in the primary 101 
tumour, in CTCs derived from the CellCollector using chip-based digital PCR [8]. 102 
Other strategies to increase the volume of blood sampled for CTCs include the use 103 
of leukapheresis [9]. However, the leukapheresis product has a very high rate of 104 
contaminating leukocytes and requires downstream enrichment methods to isolate 105 
CTCs. Compared with CellCollector, leukapheresis is also more time-consuming, 106 
expensive and onerous for patients [10].  107 
The CellCollector, like CellSearch, is limited by the dependence on EpCAM as a 108 
selection marker for CTCs, and a biologically important component of EpCAM 109 
negative CTCs will not be sampled by either technology. Marker agnostic devices 110 
based on size exclusion or biophysical properties rather than antigen expression, 111 
offer an alternative method of CTC isolation but remai  limited by the small volume 112 
of blood that can be sampled.  113 
In summary, the CellCollector appears to be a promising innovation that may help 114 
enhance our understanding of CTC biology and the mechanism of metastasis. 115 
 116 
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Figure 1A: Clinicopathological details of study cohort (SST= somatostatin, 
TAE=transarterial embolization, RFA = radiofrequency ablation, PRRT= 
Peptide radiotargeted receptor therapy) 
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Figure 1B: Examples of CTCs identified using immunofluorescent microscope, with signal for each 
channel demonstrated alongside composite image. 
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Figure 1C: Correlation between CTC identified by each operator 
for each wire enumerated 
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Figure 1D: Scattergram CTCs identified by CellCollector compared 
to CellSearch 
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 Figure 1E: Kaplan Meier survival for PFS when using 7 CTCs as threshold 
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Pt No.      Primary Grade  CTC by  
CellSearch 
CTC by  
CellCollector 
>25% Liver 
involvement  
≥3 metastatic 
sites 
01 Midgut 1 4 14 Yes Yes 
02 Midgut 1 1 2 Yes Yes 
03 PNET 2 0 2 No Yes 
04 PNET 1 1 1 Yes Yes 
05 Hindgut 2 1 1 Yes Yes 
06 Midgut 1 6 2 No Yes 
07 PNET 2 0 4 Yes Yes 
08 Midgut 1 1 2 No No 
19 PNET 2 0 4 Yes No 
10 PNET 2 0 4 Yes No 
11 PNET 3 0 2 No No 
12 Midgut 1 1 4 No No 
13 PNET 3 6 9 Yes Yes 
14 Bronchial 2 0 2 No Yes 
15 Midgut 1 57 49 Yes No 
16 PNET 1 0 8 No No 
17 PNET 2 0 0 No No 
18 Midgut 2 0 4 Yes Yes 
19 Midgut 1 0 17 Yes No 
20 Midgut 1 0 6 No No 
21 PNET 2 0 24 No Yes 
22 Midgut 1 0 14 Yes No 
23 Midgut 1 0 14 Yes Yes 
24 Midgut 1 0 6 No Yes 
25 Unknown 3 24 25 Yes Yes 
26 Midgut 1 0 16 Yes No 
27 PNET 2 0 18 Yes Yes 
28 Midgut 2 0 4 No no 
29 PNET 2 5 14 Yes Yes 
30 Midgut 1 0 6 No Yes 
31 Midgut 1 4 18 No No 
32 Midgut 2 6 7 Yes Yes 
33 Midgut 1 15 23 Yes Yes 
34 PNET 2 2 12 no Yes 
 
Table 1: Demonstrates CTC count from both CellCollector and CellSearch for all 34 patients 
that underwent successful enumeration with each isolation method. 
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